Bristol-Myers, Exelixis to work on cancer-drug candidate

11/25/2008 | Boston Globe (tiered subscription model), The

Bristol-Myers Squibb has agreed to co-develop Exelixis' XL413, an investigational cancer treatment that works by turning off Cdc7, which is said to prevent cell death in tumor cells. Exelixis will get $20 million in milestone fees from Bristol-Myers as part of the partnership, which began in January 2007.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Compliance Specialist
MJHS
Brooklyn, NY
Director of Utilization Management
Meridian Health Plan
Chicago, IL
Senior Manager, Healthcare Reform
Avalere Health
Washington, DC
Regulatory Senior Managing/Principal Engineer/Scientist
Exponent
Menlo Park, CA
Director of Claims
Meridian Health Plan
Detroit, MI